Global Antibiotic R&D Partnership (GARDP)
Daniel Lujan is an experienced Industrial Engineer currently working at Wiwynn since August 2021. Prior to this role, Daniel served as a Continuous Improvement Technician at Regal Beloit Corporation from June 2018 to August 2021, where responsibilities included assisting in line operations and training, as well as testing prototype mechanical systems. Daniel has also worked at GE Healthcare as a Material Change Coordinator from November 2016 to November 2017, focusing on the review and implementation of engineering change requests and communications regarding sourcing issues. Earlier career experience includes serving as an Electric Project Supervisor at ANZA Ingenieria S de RL from October 2013 to January 2015, managing project scope and costs. Daniel holds a Master's degree in Business Administration with a focus on Quality and Productivity from Universidad Tecmilenio (2018-2019), a Master's degree in Industrial Engineering from Universidad Autónoma de Ciudad Juárez (2015-2017), and a Bachelor's degree in Electrical and Electronics Engineering from the same institution (2006-2012).
This person is not in any offices
Global Antibiotic R&D Partnership (GARDP)
The Global Antibiotic Research & Development Partnership (GARDP) is a not-for-profit organization that develops new antibiotic treatments for drug-resistant bacterial infections that pose the greatest threat to human health, and makes them accessible to the people who need them. It puts public health needs at the centre of antibiotic drug development to address both the immediate antimicrobial resistance (AMR) crisis and to ensure people continue to get access to essential antibiotics for generations to come. GARDP works through a global network including Brazil, India, Japan, and South Africa for antibiotic development and access. Its work is made possible by essential funding from donors and collaboration with over 100 R&D and access partners in over 20 countries. GARDP was created by the World Health Organization and the Drugs for Neglected Diseases initiative (DNDi) in 2016 and legally registered as the GARDP Foundation in Geneva, Switzerland in 2018. www.gardp.org